Bren Moreno counsels pharmaceutical, biotechnology, and medical device manufacturers on a range of regulatory and compliance issues that impact their sales, marketing, and pricing activities. She advises on federal and state transparency laws, such as the federal Physician Payments Sunshine Act (Open Payments) and state drug price transparency laws. She provides counsel on these issues and others, such as state aggregate spend, gift ban, sales representative licensing, compliance program laws, and related industry standards, to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of life sciences manufacturers. Bren also regularly advises on issues related to government price-setting efforts effectuated through the Inflation Reduction Act’s Medicare Drug Price Negotiation Program and state prescription drug affordability boards (PDABs). She also has experience with pharmaceutical government pricing and price reporting matters.

After studying Biology and Bioethics at the Ohio State University, Bren attended Saint Louis University School of Law, where she served as president of the Health Law Association and Notes & Comments Managing Editor of the Journal of Health Law & Policy. 

Back to Page